DMAA on Nasdaq
Drugs Made In America Acquisition Corp.
Blank check company, listed on Nasdaq (DMAA). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerDMAA on Nasdaq1
- IndustryBlank Checks1
- HeadquartersNew York, New York1
- Business address420 Lexington Avenue, Suite 1402, New York, Ny 101702
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
Agreement”) with Titan Advisory Services LLC for the provision of such principal financial and accounting officer services by Mr.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 1 fiscal year, latest first.4
| Period ending | 2025-12-31 |
|---|---|
| General and administrative costs | $2.8M |
| Loss from operations | -$2.8M |
| Interest earned on cash and investments held in Trust Account | $8.8M |
| Total other income | $8.8M |
| NET INCOME (LOSS) | $5.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash | $6.1K | $1.4K |
| Prepaid expenses and other current assets | $6.1K | $3.6K |
| Total current assets | $12.2K | $5.0K |
| Cash and investments held in Trust Account | $239.9M | |
| Deferred offering costs | $545.8K | |
| Total non-current assets | $239.9M | $545.8K |
| TOTAL ASSETS | $239.9M | $550.8K |
| Accounts payable and accrued expenses | $222.2K | $77.3K |
| Accrued offering costs | $154.0K | $56.1K |
| Total current liabilities | $376.2K | $795.7K |
| Deferred underwriting fee payable | $6.9M | |
| Total non-current liabilities | $6.9M | |
| Total Liabilities | $7.3M | $795.7K |
| Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.43 and $0 per share as of December 31, 2025 and 2024, respectively | $239.9M | |
| Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10,717,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of December 31, 2025 and 2024, respectively(1) | $1.1K | $986 |
| Additional paid-in capital | $34.0K | |
| Accumulated deficit | -$7.3M | -$279.8K |
| Total Shareholders Deficit | -$7.3M | -$244.8K |
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS DEFICIT | $239.9M | $550.8K |
| Ordinary shares subject to possible redemption, shares (in Shares) | 23.0M shares | 0 shares |
| Ordinary shares subject to possible redemption, shares (in Dollars per share) | $10.43 | $0.00 |
| Preference shares, par value (in Dollars per share) | $0.00 | $0.00 |
| Preference shares, authorized (in Shares) | 1.0M shares | 1.0M shares |
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 |
| Ordinary shares, authorized (in Shares) | 220.0M shares | 220.0M shares |
| Ordinary shares, shares issued (in Shares) | 10.7M shares | 9.9M shares |
| Ordinary shares, outstanding (in Shares) | 10.7M shares | 9.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash | $6.1K | $1.4K |
| Prepaid expenses and other current assets | $6.1K | $3.6K |
| Total current assets | $12.2K | $5.0K |
| Cash and investments held in Trust Account | $239.9M | |
| Deferred offering costs | $545.8K | |
| Total non-current assets | $239.9M | $545.8K |
| TOTAL ASSETS | $239.9M | $550.8K |
| Accounts payable and accrued expenses | $222.2K | $77.3K |
| Accrued offering costs | $154.0K | $56.1K |
| Total current liabilities | $376.2K | $795.7K |
| Deferred underwriting fee payable | $6.9M | |
| Total non-current liabilities | $6.9M | |
| Total Liabilities | $7.3M | $795.7K |
| Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.43 and $0 per share as of December 31, 2025 and 2024, respectively | $239.9M | |
| Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10,717,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of December 31, 2025 and 2024, respectively(1) | $1.1K | $986 |
| Additional paid-in capital | $34.0K | |
| Accumulated deficit | -$7.3M | -$279.8K |
| Total Shareholders Deficit | -$7.3M | -$244.8K |
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS DEFICIT | $239.9M | $550.8K |
| Ordinary shares subject to possible redemption, shares (in Shares) | 23.0M shares | 0 shares |
| Ordinary shares subject to possible redemption, shares (in Dollars per share) | $10.43 | $0.00 |
| Preference shares, par value (in Dollars per share) | $0.00 | $0.00 |
| Preference shares, authorized (in Shares) | 1.0M shares | 1.0M shares |
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 |
| Ordinary shares, authorized (in Shares) | 220.0M shares | 220.0M shares |
| Ordinary shares, shares issued (in Shares) | 10.7M shares | 9.9M shares |
| Ordinary shares, outstanding (in Shares) | 10.7M shares | 9.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 1 fiscal year, latest first.4
| Period ending | 2025-12-31 |
|---|---|
| Net income (loss) | $5.9M |
| Payment of operating costs through promissory note | $142.0K |
| Share issuance expense | $2.0M |
| Interest earned on cash and investments held in Trust Account | -$8.8M |
| Prepaid expenses | -$6.1K |
| Accounts payable and accrued expenses | $144.9K |
| Net cash used in operating activities | -$539.2K |
| Investment of cash into Trust Account | -$231.2M |
| Net cash used in investing activities | -$231.2M |
| Proceeds from sale of Units, net of underwriting discounts paid | $228.8M |
| Proceeds from sale of Private Placement Units | $3.2M |
| Expenses paid by Sponsor under share subscription receivable | $540.8K |
| Repayment of promissory note - related party | -$900.0K |
| Payment of offering costs | $3.2K |
| Net cash provided by financing activities | $231.7M |
| Net Change in Cash | $4.8K |
| Share subscription receivable | $1.1M |
| Offering costs included in equity | $848.2K |
| Offering costs included in accrued offering costs | $94.5K |
| Deferred offering costs paid through promissory note related party | $204.0K |
| Accretion and remeasurement of redeemable ordinary shares to redemption value | $22.1M |
| Deferred underwriting fee payable | $6.9M |
| Offering costs paid via prepaid expense | $3.6K |
No quarter-by-quarter statement was filed.
Compare Drugs Made In America Acquisition Corp. with another company
Leadership
Who has led Drugs Made In America Acquisition Corp., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerLynn Stockwell Feb 4, 2025 to Feb 18, 20257
- ChairLynn Stockwell Feb 18, 2025 to Feb 18, 20258
- Chief financial officerGlenn C. Worman Jan 10, 2025 to Feb 3, 20259
Board members and other officers (5)
- OfficerLynn Stockwell Jan 10, 2025 to Jan 10, 202510
- Board memberCatherine Do Jan 10, 2025 to Feb 3, 202511
- Board memberLynn Stockwell Jan 10, 2025 to Feb 4, 202510
- Board memberMyron W. Shulgan Jan 10, 2025 to Feb 3, 202512
- Board memberSridhar G. Prasad Jan 10, 2025 to Feb 3, 202513
Timeline
- Feb 4, 2025New chief executive Lynn Stockwell becomes CEO7
Filings
76 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 14 major events, 14 insider forms, 12 large holders, 29 other. The latest 20:
- Sep 14, 2026425 CURRENT REPORT EDGAR
- Sep 14, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 202610-Q QUARTERLY REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Jul 20, 2026425 CURRENT REPORT EDGAR
- Jul 20, 20268-K CURRENT REPORT EDGAR
- Jun 26, 2026SCHEDULE 13G EDGAR
- May 14, 202610-Q QUARTERLY REPORT EDGAR
- May 5, 2026425 CURRENT REPORT EDGAR
- May 5, 20268-K CURRENT REPORT EDGAR
- May 1, 20268-K CURRENT REPORT EDGAR
- Apr 28, 20268-K CURRENT REPORT EDGAR
- Apr 16, 2026DEFR14A REVISED DEFINITIVE PROXY STATEMENT EDGAR
- Apr 15, 202610-K ANNUAL REPORT EDGAR
- Apr 14, 2026DEF 14A PROXY STATEMENT EDGAR
- Apr 8, 20268-K CURRENT REPORT EDGAR
- Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
- Mar 27, 2026PRE 14A PROXY STATEMENT EDGAR
The 76 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
6 open-market trades by officers, directors and large owners since October 2021: 4 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | Drugs Made In America Acquisition LLC10% owner | Buy | 30,000 | Form 4 | ||
| Feb 18, 2025 | Stockwell LynnCEO and Exe. Chair of Board | Buy | 30,000 | Form 4 | ||
| Jan 29, 2025 | Drugs Made In America Acquisition LLC10% owner | Buy | 400,000 | Form 4 | ||
| Jan 29, 2025 | Drugs Made In America Acquisition LLC10% owner | Sale | 5,698,363 | Form 4 | ||
| Jan 29, 2025 | Stockwell LynnCEO and Exe. Chair of Board | Buy | 400,000 | Form 4 | ||
| Jan 29, 2025 | Stockwell LynnCEO and Exe. Chair of Board | Sale | 5,698,363 | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- First Trust Capital Management L.P.SCHEDULE 13G/A, 2 filings May 15, 2025 to Aug 14, 202614
- Karpus Management, Inc.SCHEDULE 13G/A, 3 filings May 14, 2025 to Aug 14, 202615
- GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Aug 13, 202616
- Feis Equities LLCSCHEDULE 13G, 1 filing Jun 26, 202617
- Hudson Bay Capital Management LPSCHEDULE 13G/A, 2 filings May 14, 2025 to Nov 12, 202518
- Polar Asset Management Partners Inc.SCHEDULE 13G, 1 filing May 15, 202519
- Drugs Made In America Acquisition LLCSCHEDULE 13D, 1 filing Mar 3, 202520
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARLynn Stockwell, Chair
- 9
- 10SEC EDGARLynn Stockwell, Officer
- 11SEC EDGARCatherine Do, Board member
- 12SEC EDGARMyron W. Shulgan, Board member
- 13SEC EDGARSridhar G. Prasad, Board member
- 14
- 15
- 16
- 17
- 18
- 19
- 20